Jobs Simply - Vitae Pharmaceuticals News

Vitae Pharmaceuticals News

Wash. comes to Philly to listen to women business owners Monday, October 25, 2010 @ 8:29AMAn event at the Marriott near the Convention Center Tuesday emerged out of a similiar conference in Washington in early October.
PhillyInc: Women business owners get a chance to sound off Monday, October 25, 2010 @ 7:44AMFemale business owners in the Philadelphia area this week will get the chance to tell Washington what they've been facing in the postrecession era.
Curis reports net loss of $2.1 million for second-quarter 2010 Tuesday, August 3, 2010 @ 7:52AMCuris, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2010.
Vitae Pharmaceuticals Receives $14 Million Milestone Payment As Boehringer Ingelheim Advances Lead Compound Into Phase ... Thursday, July 1, 2010 @ 11:17AMVitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance ...
Vitae earns $14M milestone payment from Boehringer Ingelheim Tuesday, June 29, 2010 @ 7:24AMVitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance ...
Vitae Pharmaceuticals Receives $14 Million Milestone Payment as Boehringer Ingelheim Advances Lead Compound into Phase ... Tuesday, June 29, 2010 @ 6:30AMFORT WASHINGTON, Pa.----Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies.
Vitae receives $14M in diabetes project Tuesday, June 29, 2010 @ 5:02AMVitae Pharmaceuticals Inc., Fort Washington, said today that it received a $14 million "milestone" payment from its partner in developing a treatment for diabetes and other metabolic diseases.
BioLeap Appoints Dr. Gene Cordes to Its Board of Directors Monday, May 3, 2010 @ 11:33AMEWING, N.J. -- BioLeap, Inc., a drug design company that leverages its proprietary technology platfo...
BioLeap, Inc. Announces the Addition of Dr. Gene Cordes to Its Board of Directors Monday, May 3, 2010 @ 7:15AMEWING, N.J.----BioLeap, Inc., a drug design company that leverages its proprietary technology platform to conceive structurally-diverse, target-specific chemical entities, today announced that Dr.
Leading ladies of the Lab Friday, December 18, 2009 @ 9:27PMYou can't really blame it on Albert Einstein, but Big Al's unique look - crazy hair and strong facial expressions - has somewhat shaped the image of modern mad scientists in popular culture. Think of a scientist, and many people will think of someone eccentric and nerdy with messy hair like Einstein's, or tall, waif-ish with perfectly waxed and combed hair plus thick glasses - and all male. Of ...
Vitae Pharmaceuticals to Present at Windhover's Annual Therapeutic Area Partnerships Conference Wednesday, November 11, 2009 @ 6:30AMFORT WASHINGTON, Pa.----Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced the company’s novel, clinical-stage renin inhibitor, VTP-27999, has been recognized by Windhover as a “Top 10 Project to Watch” in the cardiovascular/metabolic disease category.
Windhover Expands Its List of Top Projects to Watch Friday, October 30, 2009 @ 12:17PMNORWALK, CT--(Marketwire - October 30, 2009) - Elsevier Business Intelligence and Windhover Conferences have announced their complete Top 10 Projects to Watch for the upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. This year's list will offer a Top 10 in each of four therapeutic areas: cardiovascular/metabolic, oncology, neuroscience and inflammatory/autoimmune. Past ...
Windhover Expands Its List of Top Projects to Watch Friday, October 30, 2009 @ 12:12PMNORWALK, CT--(Marketwire - 10/30/09) - Elsevier Business Intelligence and Windhover Conferences have announced their complete Top 10 Projects to Watch for the upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. This year's list will offer a Top 10 in each of four therapeutic areas: cardiovascular/metabolic, oncology, neuroscience and inflammatory/autoimmune. Past Windhover ...
Case Western Reserve awarded $14.7M to lead study on effects of lowering systolic blood pressure Friday, October 30, 2009 @ 4:15AMCase Western Reserve University School of Medicine has received a $14.7 million, nine-year contract from the National Institutes of Health to be one of five institutions to lead a trial to determine if lowering systolic blood pressure in hypertensive patients, without diabetes, to below the currently recommended level can reduce the incidence of cardiovascular and kidney disease and slow ...
Boehringer Ingelheim, Vitae Collaborate For Development Of Beta-Secretase Inhibitors Monday, June 15, 2009 @ 10:09AMStudy supports data from previous trial that demonstrated efficacy, safety and tolerability ... Genzyme is all set to market and sell Campath MabCampath (alemtuzumab), Fludara (fludarabine) and Le ...
(AFX UK Focus) 2009-06-15 14:09 Boehringer, Vitae ink $242 mln Alzheimer's deal Monday, June 15, 2009 @ 8:16AMLONDON, June 15 (Reuters) - Germany's Boehringer Ingelheim has signed a deal worth up to $242 million with U.S. biotech company Vitae Pharmaceuticals to research and develop new Alzheimer's drugs, the companies said on Monday. Vitae will get $42 million upfront -- consisting of cash, an equity investment and near-term research funding -- and will also be eligible for $200 million in ...
Boehringer, Vitae ink $242 mln Alzheimer's deal Monday, June 15, 2009 @ 7:54AM* $42 mln upfront, $200 mln pre-commercial milestones
Vitae Pharmaceuticals gets $13M in financing Tuesday, October 28, 2008 @ 12:39PMVitae Pharmaceuticals Inc. entered into a $13 million loan agreement Tuesday with Silicon Valley Bank and Oxford Finance Corp.
Vitae Pharmaceuticals Secures $13 Million in Debt Financing Tuesday, October 28, 2008 @ 7:00AM FORT WASHINGTON, Pa.----Vitae Pharmaceuticals, Inc., an emerging pharmaceutical company dedicated to the discovery and development of innovative small molecule medicines, announced today that it has further strengthened its operating runway by entering into a $13 million loan agreement with Silicon Valley Bank and Oxford Finance Corporation.
Vitae Pharmaceuticals Announces Promotion of Tina Fiumenero to Chief Financial Officer Thursday, October 23, 2008 @ 7:35AMVitae Pharmaceuticals, Inc., an emerging pharmaceutical company dedicated to the discovery and development of innovative small molecule medicines, announced today that it has promoted Tina Fiumenero to the position of Chief Financial Officer.
Vitae Pharmaceuticals reacquires rights to renin inhibitor program Wednesday, October 22, 2008 @ 7:43PMVitae Pharmaceuticals, a developer of small molecule medicines, has reacquired full rights to its renin inhibitor program and is advancing the program towards the clinic.
Vitae reacquires renin inhibitor rights Tuesday, October 21, 2008 @ 10:57AMVitae Pharmaceuticals Inc. said Tuesday it has reacquired full rights to its renin inhibitor program. (GSK)
Vitae Pharmaceuticals to Reacquire Full Rights to Renin Inhibitor Program for Hypertension Tuesday, October 21, 2008 @ 8:00AM FORT WASHINGTON, Pa.----Vitae Pharmaceuticals, Inc., an emerging pharmaceutical company dedicated to the discovery and development of innovative small molecule medicines, announced today that it has reacquired full rights to its renin inhibitor program and is advancing the program towards the clinic.
Boehringer unveils R&D entry into type-2 diabetes arena Tuesday, October 21, 2008 @ 7:52AMBoehringer Ingelheim announced that patients and physicians may have several innovative type-2 diabetes treatment alternatives available in the coming years.
My Pharmiweb.com Tuesday, October 21, 2008 @ 5:48AMIngelheim, Germany and Biberach, Germany. Friday 17 October 2008: Boehringer Ingelheim announced that patients and physicians may have several innovative type 2 diabetes treatment alternatives available in the coming years.
Interview: UK science minister Lord Drayson Monday, October 20, 2008 @ 6:17PM It was on a family holiday to the Kennedy Space Centre in Florida that the new science minister, Lord Drayson, really understood the power that astronauts have to inspire. "The tour guide asked all the children aged between eight and 15 to put their hands up. She said that they were eligible to join the Nasa astronaut programme to fly to Mars," he says. His five kids were captivated. "Now my ...
JMP Securities Healthcare Conference to Be Held in New York Wednesday, October 1, 2008 @ 4:51PMJMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that its broker-dealer subsidiary, JMP Securities, will host the third annual JMP Securities Healthcare Focus Conference at Le Parker Meridien in New York on Monday and Tuesday, October 6 and 7, 2008.
JMP Securities Healthcare Conference to Be Held in New York Wednesday, October 1, 2008 @ 4:25PM SAN FRANCISCO----JMP Group Inc. , an investment banking and alternative asset management firm, announced today that its broker-dealer subsidiary, JMP Securities, will host the third annual JMP Securities Healthcare Focus Conference at Le Parker Meridien in New York on Monday and Tuesday, October 6 and 7, 2008.